Pharmacogenetics in the treatment of breast cancer
- 16 March 2004
- journal article
- review article
- Published by Springer Nature in The Pharmacogenomics Journal
- Vol. 4 (3) , 143-153
- https://doi.org/10.1038/sj.tpj.6500242
Abstract
No abstract availableKeywords
This publication has 55 references indexed in Scilit:
- A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast CancerNew England Journal of Medicine, 2003
- Inherited and Acquired Risk Factors for Venous Thromboembolic Disease Among Women Taking Tamoxifen to Prevent Breast CancerJournal of Clinical Oncology, 2003
- Welcome to the Genomic EraNew England Journal of Medicine, 2003
- Distinct prevalence of the CYP19 Δ3(TTTA)7 allele in premenopausal versus postmenopausal breast cancer patients, but not in control individualsEuropean Journal Of Cancer, 2002
- Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trialThe Lancet, 2002
- Gene expression profiling predicts clinical outcome of breast cancerNature, 2002
- Genetic variants of CYP19 (aromatase) and breast cancer riskOncogene, 2000
- Endometrial Carcinoma in Tamoxifen-Treated Breast Cancer PatientInternational Journal of Gynecological Pathology, 1999
- Clinical Pharmacokinetics of DocetaxelClinical Pharmacokinetics, 1999
- A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductaseNature Genetics, 1995